Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Liraglutide 3 mg (Saxenda) a once-daily GLP-1 receptor agonist licensed for obesity management (NICE TA664)
Many patients benefit from a gradual dose escalation schedule that reduces nausea and gastrointestinal side effects while keeping early costs minimal
They are complementary, not competitors
Its mechanism of action includes: Stimulating insulin production from the pancreas Reducing sugar production in the liver Slowing digestion to help with appetite control Supporting long-term weight management Although the precise way semaglutide injection protects kidney function is not fully understood, its benefits in diabetes management and cardiovascular health are well-documented
They add gas to an already slow-moving digestive system, worsening bloating and discomfort
